Autopsy report · NCT04925778

Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate

“Business considerations”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Banner Life Sciences LLC

Sponsor type

Industry

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

monomethyl fumarate

Participants

0

Trials that died the same way

• A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
  “Strategic considerations” (74% match in meaning)
• Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
  “Business Decision” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.